Immunocore Hldgs Ads1 Stock Net Income
| 6YG Stock | EUR 27.00 0.60 2.27% |
As of the 16th of February 2026, IMMUNOCORE HLDGS retains the market risk adjusted performance of (0.08), and Risk Adjusted Performance of (0). IMMUNOCORE HLDGS technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out IMMUNOCORE HLDGS ADS1 standard deviation, information ratio, maximum drawdown, as well as the relationship between the variance and treynor ratio to decide if IMMUNOCORE HLDGS is priced correctly, providing market reflects its last-minute price of 27.0 per share.
IMMUNOCORE HLDGS's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing IMMUNOCORE HLDGS's valuation are provided below:Gross Profit 334.4 M | Profit Margin | Market Capitalization 1.4 B | Enterprise Value Revenue 3.0985 | Revenue |
IMMUNOCORE |
IMMUNOCORE HLDGS 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to IMMUNOCORE HLDGS's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of IMMUNOCORE HLDGS.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in IMMUNOCORE HLDGS on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding IMMUNOCORE HLDGS ADS1 or generate 0.0% return on investment in IMMUNOCORE HLDGS over 90 days. IMMUNOCORE HLDGS is related to or competes with Samsung Electronics, WOORI FIN, POSCO Holdings, Toyota, MEBUKI FINANCIAL, Fukuoka Financial, and LG Electronics. Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology,... More
IMMUNOCORE HLDGS Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure IMMUNOCORE HLDGS's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess IMMUNOCORE HLDGS ADS1 upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 11.24 | |||
| Value At Risk | (4.05) | |||
| Potential Upside | 4.55 |
IMMUNOCORE HLDGS Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for IMMUNOCORE HLDGS's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as IMMUNOCORE HLDGS's standard deviation. In reality, there are many statistical measures that can use IMMUNOCORE HLDGS historical prices to predict the future IMMUNOCORE HLDGS's volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (0.09) |
IMMUNOCORE HLDGS February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 1.94 | |||
| Coefficient Of Variation | (7,584) | |||
| Standard Deviation | 2.56 | |||
| Variance | 6.56 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 11.24 | |||
| Value At Risk | (4.05) | |||
| Potential Upside | 4.55 | |||
| Skewness | 0.4404 | |||
| Kurtosis | 0.354 |
IMMUNOCORE HLDGS ADS1 Backtested Returns
IMMUNOCORE HLDGS ADS1 holds Efficiency (Sharpe) Ratio of -0.12, which attests that the entity had a -0.12 % return per unit of volatility over the last 3 months. IMMUNOCORE HLDGS ADS1 exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out IMMUNOCORE HLDGS's market risk adjusted performance of (0.08), and Risk Adjusted Performance of (0) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IMMUNOCORE HLDGS's returns are expected to increase less than the market. However, during the bear market, the loss of holding IMMUNOCORE HLDGS is expected to be smaller as well. At this point, IMMUNOCORE HLDGS ADS1 has a negative expected return of -0.28%. Please make sure to check out IMMUNOCORE HLDGS's standard deviation, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if IMMUNOCORE HLDGS ADS1 performance from the past will be repeated at future time.
Auto-correlation | 0.36 |
Below average predictability
IMMUNOCORE HLDGS ADS1 has below average predictability. Overlapping area represents the amount of predictability between IMMUNOCORE HLDGS time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of IMMUNOCORE HLDGS ADS1 price movement. The serial correlation of 0.36 indicates that just about 36.0% of current IMMUNOCORE HLDGS price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 0.86 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, IMMUNOCORE HLDGS ADS1 reported net income of (84.49 Million). This is 124.76% lower than that of the Biotechnology sector and 220.62% lower than that of the Health Care industry. The net income for all Germany stocks is 114.8% higher than that of the company.
IMMUNOCORE Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IMMUNOCORE HLDGS's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IMMUNOCORE HLDGS could also be used in its relative valuation, which is a method of valuing IMMUNOCORE HLDGS by comparing valuation metrics of similar companies.IMMUNOCORE HLDGS is currently under evaluation in net income category among its peers.
IMMUNOCORE Fundamentals
| Return On Equity | -0.0755 | ||||
| Return On Asset | -0.0155 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 991.07 M | ||||
| Shares Outstanding | 50.53 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 99.97 % | ||||
| Price To Book | 4.08 X | ||||
| Price To Sales | 3.66 X | ||||
| Revenue | 379.59 M | ||||
| Gross Profit | 334.36 M | ||||
| EBITDA | (23.46 M) | ||||
| Net Income | (84.49 M) | ||||
| Cash And Equivalents | 313.08 M | ||||
| Cash Per Share | 8.14 X | ||||
| Total Debt | 63.78 M | ||||
| Debt To Equity | 0.26 % | ||||
| Current Ratio | 6.23 X | ||||
| Book Value Per Share | 6.62 X | ||||
| Cash Flow From Operations | (56.03 M) | ||||
| Earnings Per Share | (0.49) X | ||||
| Target Price | 68.87 | ||||
| Number Of Employees | 493 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 1.39 B |
About IMMUNOCORE HLDGS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IMMUNOCORE HLDGS ADS1's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IMMUNOCORE HLDGS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IMMUNOCORE HLDGS ADS1 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in IMMUNOCORE Stock
IMMUNOCORE HLDGS financial ratios help investors to determine whether IMMUNOCORE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in IMMUNOCORE with respect to the benefits of owning IMMUNOCORE HLDGS security.